Research programme: RhoB modulators - Evotec SE/Inserm Transfert
Latest Information Update: 28 Oct 2020
Price :
$50 *
At a glance
- Originator Evotec AG; Inserm Transfert
- Developer Evotec SE; Inserm Transfert
- Class
- Mechanism of Action Rho-associated kinase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer